BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this … Read more
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).
Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more
The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more
A study published in October showed that high-grade serous ovarian carcinomas (HGSOC), which account for about 75 percent of ovarian cancers, originate with abnormal cells in the fallopian tubes an average of seven years before the disease develops. This understanding … Read more
Whether you’ve already been diagnosed, or you want to know your risk, health experts can test your DNA to determine your chances of developing cancer.
“The testing itself determines whether or not they have inherited this broken gene that could … Read more
Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more
PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more
Myriad Genetics had been exclusively providing tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been … Read more
Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.
Results showed a median PFS of … Read more
Over the past 20 years, Nazneen Rahman has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers—work that has earned her scientific, popular, and even royal acclaim. But her latest accomplishment, and one … Read more
